Literature DB >> 16277549

Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states.

Paul Kind1, Susan Macran.   

Abstract

BACKGROUND: The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a multidimensional measure of quality of life developed for use in the evaluation of interventions in lung cancer.
OBJECTIVE: To develop a set of utility weights that could be used to convert FACT-L into a single index capable of being used in the economic analysis of clinical trial data.
METHOD: A core set of FACT-L items were valued in two versions of a 14-page postal survey of over 400 members of the UK general population. Respondents valued hypothetical FACT-L health states using a scale from 0 to 100 (worst to best health state). Respondents also valued their own health using the standard form of the EuroQol EQ-5D. Data were entered into an ordinary least squares regression model.
RESULTS: Item weights estimated in regression analysis yielded values for 10 items from the FACT-L. The summary index based on this selected set of FACT-L items has a maximum value of 0.703 and a minimum value of 0.111.
CONCLUSION: This study demonstrates a practical method of converting a standard condition-specific measure into a form that has the requisite properties to legitimise its use in cost-utility analysis. The methodology used here is not unique to FACT-L and might be considered appropriate for use in converting similar instruments.

Entities:  

Mesh:

Year:  2005        PMID: 16277549     DOI: 10.2165/00019053-200523110-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  "Death" and the valuation of health-related quality of life.

Authors:  S Macran; P Kind
Journal:  Med Care       Date:  2001-03       Impact factor: 2.983

2.  Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials.

Authors:  A Bagust; M Barraza-Llorens; Z Philips
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

Review 3.  Multi-attribute health status classification systems. Health Utilities Index.

Authors:  D Feeny; W Furlong; M Boyle; G W Torrance
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

Review 4.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

5.  Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.

Authors:  S Trippoli; M Vaiani; C Lucioni; A Messori
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme.

Authors:  T L Griffiths; C J Phillips; S Davies; M L Burr; I A Campbell
Journal:  Thorax       Date:  2001-10       Impact factor: 9.139

7.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

8.  Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment.

Authors:  Clifford Y Ko; Melinda Maggard; Edward H Livingston
Journal:  J Surg Res       Date:  2003-09       Impact factor: 2.192

Review 9.  Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Authors:  C Czoski-Murray; E Warren; J Chilcott; C Beverley; M A Psyllaki; J Cowan
Journal:  Health Technol Assess       Date:  2004-04       Impact factor: 4.014

  9 in total
  16 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoL™).

Authors:  Andrew Lloyd; Cicely Kerr; Katie Breheny; John Brazier; Aurora Ortiz; Emma Borg
Journal:  Qual Life Res       Date:  2013-09-13       Impact factor: 4.147

3.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Eliciting social preference weights for functional assessment of cancer therapy-lung health states.

Authors:  A Simon Pickard; Deborah Dobrez; David Cella
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation.

Authors:  Jonathan W Kowalski; Anne M Rentz; John G Walt; Andrew Lloyd; Jeff Lee; Tracey A Young; Wen-Hung Chen; Neil M Bressler; Paul Lee; John E Brazier; Ron D Hays; Dennis A Revicki
Journal:  Qual Life Res       Date:  2011-08-04       Impact factor: 4.147

Review 6.  Using QALYs in cancer: a review of the methodological limitations.

Authors:  Martina Garau; Koonal K Shah; Anne R Mason; Qing Wang; Adrian Towse; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

7.  Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.

Authors:  C M McDonough; M R Grove; A D Elledge; A N A Tosteson
Journal:  Osteoporos Int       Date:  2011-04-12       Impact factor: 4.507

Review 8.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

9.  Quantitative Preferences for Lung Cancer Treatment from the Patients' Perspective: A Systematic Review.

Authors:  Yasuo Sugitani; Naoko Sugitani; Shunsuke Ono
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

10.  Predicting SF-6D utility scores from the Oswestry disability index and numeric rating scales for back and leg pain.

Authors:  Leah Y Carreon; Steven D Glassman; Christine M McDonough; Raja Rampersaud; Sigurd Berven; Michael Shainline
Journal:  Spine (Phila Pa 1976)       Date:  2009-09-01       Impact factor: 3.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.